Bibliographic analysis of the use of laboratory blood parameters for the prognosis of primary lung cancer;Analyse critique de la bibliographie sur l'utilisation de parametres biologiques sanguins pour l'evaluation pronostique du cancer bronchopulmonaire primitif

Annales de Biologie Clinique

Volumn 57, Issue 1, 1999, Pages 57-68

  Watine, J ^a   Rouzaud, P ^a   Charet, J C ^b  

^a Hopital de Rodez   (France)

^b NONE

Author keywords

Blood laboratory parameters; Bronchogenic carcinoma; Laboratory expertise; Prognosis

Indexed keywords

CALCIUM; CYTOKERATIN 19 FRAGMENT; OROSOMUCOID; SERUM ALBUMIN;

ARTICLE; BLOOD LEVEL; CALCIUM BLOOD LEVEL; HUMAN; LABORATORY TEST; LUNG NON SMALL CELL CANCER; PROGNOSIS; PROTHROMBIN TIME; PUBLICATION;

ANTIGENS, NEOPLASM; CALCIUM; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; HUMANS; KERATINS; LUNG NEOPLASMS; MULTIVARIATE ANALYSIS; PROGNOSIS; SERUM ALBUMIN; TUMOR MARKERS, BIOLOGICAL;

EID: 0033010730     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (123)

1. American Thoracic Society and European Respiratory Society. Pretreatment Evaluation of Non-Small-cell Lung Cancer. Am J Respir Crit Care Med 1997 ; 156 : 320-32.
2. Bruderman I. Bronchogenic Carcinoma. In : Baum GL, Wolinsky E, eds. Texbook of pulmonary diseases. 5th edition. Little. Brown and Company, New York, 1994 : 1345-92.
3. Ginsberg RJ, Kris MG, Armstrong JG. Non-small cell lung cancer. In : De Vita VT, Hellman S, Rosenberg SA, eds. Cancer. Principles and practice of oncology. Fourth Edition. JB Lippincott Company. Philadelphia, 1993 : 673-723.
4. Ihde DC, Pass HI, Glatstein EJ. Small cell lung cancer. In : De Vita VT, Hellman S, Rosenberg SA, eds. Cancer. Principles and practice of oncology. Fourth Edition. JB Lippincott Company, Philadelphia, 1993 : 723-58.
5. Société de pneumologie de langue française. Recommandations concernant l'utilisation des marqueurs tumoraux sériques dans la prise en charge des cancers bronchiques primitifs. Rev Mal Resp 1997 ; 14 : 3S5-3S39.
6. Buccheri G, Ferrigno D. Prognostic factors in lung cancer : tables and comments. Eur Respir J 1994 ; 7 : 1350-64.
7. Fielding LP, Fenoglio-Preiser CM, Freedman LS. The future of prognostic factors in outcome prediction for patients with cancer. Cancer 1992 ; 70 : 2367-77.
8. Watine J, Charet JC. Faut-il suivre les sociétés savantes de pneumologie dans leurs recommandations concernant l'utilisation des marqueurs tumoraux sériques pour l'évaluation pronostique des cancers bronchiques primitifs non à petites cellules ? Rev Mal Resp 1998 ; in press.
9. Watine J, Charet JC. Do blood cell counts and/or differencial have an independent pretherapeutic prognostic value in primary lung cancer ? Hematol Cell Ther 1998 ; 40 : 99-106.
10. Watine J, Charet JC. Est-il nécessaire de doser en routine les marqueurs tumoraux sériques, et en particulier la NSE (neuron specific enolase), pour l'évaluation pronostique des patients porteurs de cancer bronchique primitif à petites cellules ? Presse Méd 1998 ; in press.
11. Watine J, Charet JC, Augé MC. À propos de la prescription de marqueurs tumoraux sériques dans un hôpital général. Presse Méd 1998 ; 27 : 862.
12. Lebeau B. Analyse bibliographique quantitative de la recherche clinique française en thérapeutique des cancers bronchopulmonaires. Rev Mal Respir 1998 ; 15 : 185-9.
13. IFCC committee on systematic reviewing in laboratory medicine. Systematic reviewing in laboratory medicine. Journal of the IFCC 1997 ; 9 : 154-5.
14. Albain KS, Crowley JJ, Hutchins L, et al. Predictors of survival following relapse or progression of small cell lung cancer. Cancer 1993 ; 72 : 1184-91.
15. Albain KS, Crowley JJ, Leblanc M, Livingston RB. Determinants of improved outcome in small cell lung cancer : an analysis of the 2,580 patients Southwest Oncology Group data base. J Clin Oncol 1990 ; 8 : 1563-74.
16. Albain KS, Crowley JJ, Livingston RB. Long-term survival and toxicity in small cell lung cancer : expanded Southwest Oncology Group experience. Chest 1991 ; 99 : 1425-32.
17. Allan SG, Stewart ME, Love S, Cornbleet MA, Smyth JF, Leonard RCF. Prognosis at presentation of small cell carcinoma of the lung. Eur J Cancer 1990 ; 26 : 703-5.
18. Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N. Pretreatment prognosis factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer 1987 ; 39 : 146-9.
19. Clamon GH, Feld R, Evans WK, et al. The effect of adjuvant central intra venous hyperalimentation on the survival and response to treatment of patients with small cell lung cancer : a randomized trial. Cancer Treat Rep 1985 ; 69 : 167-77.
20. Cohen MH, Makuch R, Johnston-Early A, et al. Laboratory parameters as an alternative to performance status in pronostic stratification of patients with small cell lung cancer. Cancer Treat Rep 1981 ; 65 : 187-95.
21. Dearing MP, Steinberg SM, Phelps R, et al. Outcome of patients with small cell lung cancer: effects of changes in staging procedures and imaging technology on prognostic factors over 14 years. J Clin Oncol 1990 ; 8 : 1042-9.
22. De Wet M, Falkson G, Rapoport BL. Small cell lung cancer : analysis of factors influencing the response to treatment and survival. Oncology 1994 ; 51 : 523-34.
23. Fischer JR, Schindel M, Bülzebruck H, Lahm H, Krammer PH, Drings P. Decrease of interleukin-2 secretion is a new indépendent prognostic factor associated with poor survival in patients with small-cell lung cancer. Ann Oncol 1997 ; 8 : 457-61.
24. Giovanella L, Piantanida R, Ceriani L, et al. Immunoassay of neuron-specific enolase (NSE) and serum fragments of cytokeratin 19 (Cyfra 21-1) as tumor markers in small cell lung cancer : clinical evaluation and biological hypothesis. Int J Biol Markers 1997 ; 12 : 22-6.
25. Graus F, Dalmau J, René R, et al. Anti-Hu antibodies in patients with small-cell lung cancer : association with complete response to therapy and improved survival. J Clin Oncol 1997 ; 15 : 2866-72.
26. Gronowitz JS, Bergström R. Nôu E, et al. Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis. Cancer 1990 ; 66 : 722-32.
27. Gronawitz JS, Steinholtz L, Källander CFR, Hagberg H, Bergh J. Serum deoxythymidine kinase in small cell lung carcinoma of the lung. Relation to clinical features, prognosis, and other biochemical markers. Cancer 1986 ; 58 : 111-8.
28. Gross AJ, Steinberg SM, Reilly JG, et al. Atrial natriuretic factor and arginine vasopressin production in tumor cell lines from patients with lung cancer and their relationship to serum sodium. Cancer Res 1993 ; 53 : 67-74.
29. Hosker HSR, Jones GM, Corris PA. The nutritional status of patients with small cell lung cancer before and during treatment with chemotherapy. Lung Cancer 1991 ; 7 (suppl.) : 49 (abstract 175).
30. Johnson PWM, Joel SP, Love S, et al. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer 1993 ; 67 : 760-6.
31. Joos G, Pinson Ph, Watripont P, Brusselle G, Pauwels R. A retrospective analysis of serum NSE and CEA in small cell lung cancer. Lung Cancer 1991 ; 7 (suppl.) : 59 (abstract 214).
32. Jorgensen LGM, Hirsch FR, Skov BG, Østerlind K, Cooper EH, Larsson LI. Occurrence of neuron specific enolase in tumour tissue and serum in small cell lung cancer. Br J Cancer 1991 ; 63 : 151-3.
33. Jorgensen LGM, Østerlind K, Genolla J, et al. Serum neuron specific enolase (S-NSE) and the prognosis in small-cell lung cancer : a combined multivariable analysis on data from nine centres. Br J Cancer 1996 ; 74 : 463-7 (erratum : page 2043).
34. Jorgensen LGM, Østerlind K, Hansen HH, Cooper EH. The pronostic influence of serum neuron specific enolase in small cell lung cancer. Br J Cancer 1988 ; 58 : 805-7.
35. Kawahara M, Fukuoka M, Saijo N, et al. Prognostic factors and prognostic staging system for small cell lung cancer. Jpn J Clin Oncol 1997 ; 27 : 158-65.
36. Kelbel C, Omid S, Westermeier T, Lorenz J. Prognosefaktoren des kleinzelligen Bronchialkarzinoms. Pneumologie 1994 ; 48 : 475-80.
37. Lassen U, Østerlind K, Hansen M, Dombernowsky P, Bergman B, Hansen HH. Long-term survival in small-cell lung cancer : post-treatment characteristics in patients surviving 5 to 18+ years ; an analysis of 1,714 consecutive patients. J Clin Oncol 1995 ; 13 : 1215-20.
38. Maetsu I, Pastor M, Gomez-Codina J, et al. Pretreatment prognostic factors for survival in small cell lung cancer : a new prognostic index and validation of three known prognostic indices on 341 patients. Ann Oncol 1997 ; 8 : 547-53.
39. Milleron B, Cadranel LJ, Lioté H, François T, Scarna H, Akoun G. Prognostic value of serum neuron-specific enolase in small cell lung cancer. Lung Cancer 1988 ; 4 (suppl.) : A47 (abstract 4.1.11).
40. Niederle N, Eberhardt W, Hirche H. Prätherapeutische prognostische Factoren beim kleinzelligen Bronchialkarzinom. Onkologie 1988 ; 11 (suppl. 2) : 34-40.
41. Ohnoshi T, Hiraki S, Nakata Y, et al. Pretreatment serum albumin concentration and lactic dehydrogenase activity as prognostic factors with small cell lung cancer. Acta Med Okayama 1982 ; 36 : 487-90.
42. Østerlind K, Andersen PK. Prognostic factors in small cell lung cancer : multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 1986 ; 46 : 4189-94.
43. Østerlind K, Ciampi A, Dombernowsky P, Hansen M, Hansen OP, Hansen HH. Prognostic factors in small cell lung cancer (SCLC). RECPAM analysis on 1.651 pts treated in Copenhagen during 1973-1987. Lung Cancer 1991 ; 7 (suppl.) : 58 (abstract 211).
44. Østerlind K, Hansen HH, Hansen M, Dombernowsky P, Andersen PK. Long-term disease-free survival in small-cell carcinoma of the lung : a study of clinical determinants. J Clin Oncol 1986 ; 4 : 1307-13.
45. Østerlind K, Jorgensen LGM, Hansen HH, Cooper EM. Neuron specific enolase (NSE). A sensitive prognostic factor in small cell lung cancer (SCLC). Lung Cancer 1988 ; 4 (suppl.) : A48 (abstract 4.1.15).
46. Quoix E, Hedelin G, Popin E, et al. Can we predict very short term survival in small cell lung cancer ? Lung Cancer 1993 ; 10 : 229-38.
47. Quoix E, Hedelin G, Seibert R, et al. Facteurs pronostiques préthérapeutiques de la survie dans le cancer bronchique à petites cellules. Étude rétrospective d'une série de 112 patients. Rev Mal Resp 1993 ; 10 : 29-35.
48. Quoix E, Hedelin G, Seibert R, et al. Prédiction d'une survie très courte (2 mois) dans le cancer bronchique à petites cellules. Rev Mal Resp 1991 ; 8 (suppl. 1) : R23 (abstract A80).
49. Rawson NSB, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 1990 ; 61 : 597-604.
50. Rosenfeld MR, Malats N, Schramm L, et al. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. J Natl Cancer Inst 1997 ; 89 : 381-5.
51. Rosti G, Nanni O, Leoni M, Fiorentini G, Tienghi A, Marangolo M. Prognostic factors affecting survival in small cell lung cancer patients. Lung Cancer 1988 ; 4 (suppl) : A51 (abstract 4.1.27).
52. Sagman U, Feld R, Lishner M, et al. Long term survival of patients with Small Cell Lung Cancer ; Analysis of prognostic factors. Lung Cancer 1988 ; 4 (suppl.) : A45 (abstract 4.1.04).
53. Sagman U, Leblanc M, Maki E, Feld R and the consensus group for prognostic factors in SCLC. Verification of a multicenter prognostic model for small-cell lung carcinoma. Proc Am Soc Clin Oncol 1993 ; 12 : 337 (abstract 1125).
54. Sagman U, Maki E, Evans WK, et al. Small-cell carcinoma of the lung : derivation of a pronostic staging system. J Clin Oncol 1991 ; 9 : 1639-49.
55. Sagman U, Maki E, Ledesma E, Feld R and the Consensus Group for Prognostic Factors in SCLC. A multicentre consensus model for prognostic factors in small cell lung cancer (SCLC). Lung cancer 1991 ; 7 (suppl.) : 58 (abstract 213).
56. Sheehan RG, Balaban EP, Cox JV, Frenkel EP. The relative value of conventional staging procedures for developing prognostic models in extensive-stage small cell lung cancer. J Clin Oncol 1990 ; 8 : 2047-53.
57. Sheehan RG, Balaban EP, Frenkel EP. The impact of dose intensity of standard chemotherapy regimens in extensive stage small cell lung cancer. Am J Clin Oncol 1993 ; 16 : 250-5.
58. Shikaura S, Kawa S, Yoshida M, Yonezu S. Results of chemo-radiotherapy and prognostic factors of small cell lung cancer. Radiation Medicine 1991 ; 9 : 70-6.
59. Souhami RL, Bradbury I, Geddes DM, Spiro SG, Harper PG, Tobias JS. Prognostic significance of laboratory parameters measured at diagnosis in small-cell carcinoma of the lung. Cancer Res 1985 ; 45 : 2878-82.
60. Souhami RL, Earl HM, Ash CM, Spiro SG, Geddes D, Harper PG, Tobias JS. Prognostic factors in patients with small-cell lung cancer : preliminary results from a large randomised study. Antibiot Chemother 1988 ; 41 : 77-82.
61. Van der Gaast A, Van Putten WLJ, Oosterom R, Cozijnsen M, Hoekstra R, Splinter TAW. Prognostic value of serum thymidine kinase, tissue polypeptide antigen and neuron specific enolase in patients with small cell lung cancer. Br J Cancer 1991 ; 64 : 369-72.
62. Vincent MD, Ashley SE, Smith IE. Pronostic factors in small cell lung cancer : a simple prognostic index is better than conventional staging. Eur J Cancer Clin Oncol 1987 ; 23 : 1589-99.
63. Wang T, Feld R, Sagman U, et al. The combined use of LDH and CEA as independent prognostic markers for small cell lung cancer. Proc Am Assoc Cancer Res 1986 ; 27 : 162 (abstract 641).
64. Wojtukiewicz MZ, Zacharski LR, Moritz TE, Hur K, Edwards RL, Rickles FR. Prognostic significance of blood coagulation tests in carcinoma of lung and colon. Blood Coag Fibrin 1992 ; 3 : 429-37.
65. Work E, Bentzen SM, Nielsen OS, Fode K, Michalski W, Palshof T and The Aarhus Lung Cancer Group. Prophylactic cranial irradiation in limited stage small cell lung cancer : survival benefit in patient with favourable characteristics. Eur J Cancer 1996 ; 32A : 772-8.
66. Albain KS, Crowley JJ, Leblanc M, Livingston RB. Survival determinants in extensive stage non-small cell lung cancer : the Southwest Oncology Group Experience. J Clin Oncol 1991 ; 9 : 1618-26.
67. Andoh M, Gemma A, Takenaka K, et al. Serum neuron specific enolase level as a prognostic factor in non-small cell lung cancer. Internal Medicine 1994 ; 33 : 271-6.
68. Benichou J, Fabre C, Chaslang CI, et al. Facteurs pronostiques du cancer du poumon opéré non à petites cellules : étude à partir d'un essai thérapeutique randomisé. Rev Mal Respir 1987 ; 4 : 301-9.
69. Bréchot JM, Chevret S, Nataf J, et al. Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer 1997 ; 33 : 385-91.
70. Buccheri G, Ferrigno D, Vola F. Carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and other prognostic indicators in squamous cell lung cancer. Lung Cancer 1993 ; 10 : 21-33.
71. Buccheri G, Ferrigno D, Vola F, Rosso A. Multivariate survival analysis of 360 patients with squamous cell lung cancer (SCLC). Lung Cancer 1991 ; 7 (suppl.) : 46 (abstract 165).
72. Engan T, Hannisdal E. Blood analyses as prognostic factors in primary lung cancer. Acta Oncol 1990 ; 29 : 151-4.
73. Espinoza E, Feliu J, Zamora P, et al. Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. Lung Cancer 1995 ; 12 : 67-76.
74. Evans WK, Nixon DW, Daly JM, et al. A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. J Clin Oncol 1987 ; 5 : 113-4.
75. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer : an Eastern Cooperative Oncology Group Study. J Clin Oncol 1986 ; 4 : 702-9.
76. Gail MH, Eagan RT, Feld R, and the Lung Cancer Study Group. Prognostic factors in patients with resected stage 1 non-small cell lung cancer. A report from the lung cancer study group. Cancer 1984 ; 54 : 1802-13.
77. Hespanhol V, Queiroga H, Magalhaes A, Santos AR, Coelho M, Marques A. Survival predictors in advanced non-small cell lung cancer. Lung Cancer 1995 ; 13 : 253-67.
78. Kanda T, Soda H, Hirose K, et al. Prognostic factors of the pulmonary adenocarcinoma. Lung Cancer 1988 ; 4 (suppl.) : A54 (abstract 4.2.06).
79. Kojima A, Shinkai T, Eguchi K, et al. Analysis of three year survivors among patients with advanced inoperable non-small cell lung cancer. Jpn J Clin Oncol 1991 ; 21 : 276-81.
80. Moro D, Villemain D, Vuillez JP, Agnius Delord C, Brambilla C. CEA, Cyfra 21-1 and SCC in non-small cell lung cancer. Lung Cancer 1995 ; 13 : 169-76.
81. Muers MF, Shevlin P, Brown J on behalf of the participating members of the Thoracic Group of the Yorkshire Cancer Organisation. Prognosis in lung cancer : physicians' opinions compared with outcome and a predictive model. Thorax 1996 ; 51 : 894-902.
82. Niklinski J, Furman M, Burzykowski T, Chyczewski L, Chyczewska E, Rapellino M. Preoperative Cyfra 21-1 level as a prognostic indicator in resected primary squamous cell lung cancer. Br J Cancer 1996 ; 74 : 956-60.
83. O'Connell JP, Kris MG, Gralla RJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy. J Clin Oncol 1986 ; 4 : 1604-14.
84. Ohlhauser C, Bülzebruck H, Ebert W, Drings P, Wannenmacher M. Prognostic factors for survival in inoperable non-small cell lung cancer : a multivariate regression analysis of 456 patients with radiation therapy. Onkologie 1997 ; 20 : 126-31.
85. Paesmans M, Sculier JP, Libert P, et al. for the European Lung Cancer Working Party. Prognostic factors for survival in advanced non-small-cell lung cancer : univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol 1995 ; 13 : 1221-30.
86. Pujol JL, Cooper EH, Grenier J, et al. Clinical evaluation of serum tissue polypeptide antigen (TPS) in non-small cell lung cancer. Eur J Cancer 1994 ; 30A : 1768-74.
87. Pujol JL, Grenier J, Parrat E, et al. Cytokeratins as serum markers in lung cancer : a comparison of Cytra 21-1 and TPS. Am J Respir Crit Care Med 1996 ; 154 : 725-33.
88. Sculier JP, Paesmans M, Libert P, et al. et les membres de l'European Lung Cancer Working Party. Facteurs pronostiques des cancers bronchiques non à petites cellules au stade avancé. Expérience de l'European Lung Cancer Working Party. Rev Mal Respir 1997 ; 14(6) : 445-9.
89. Sculier JP, Paesmans M, Libert P, et al. for the European Lung Cancer Working Party. Long-term survival after chemotherapy containing platinium derivatives in patients with advanced non-small cell lung cancer. Eur J Cancer 1994 ; 30A : 1342-7.
90. Shinkai T, Eguchi K, Sasaki Y, et al. A prognostic-factor risk index in advanced non-small cell lung cancer treated with cisplatin-containing combination chemotherapy. Cancer Chemother Pharmacol 1992 ; 30 : 1-6.
91. Sorensen JB, Badsherg JH, Olsen J. A multivariate regression analysis of prognostic factors in 259 consecutive patients with inoperable adenocarcinoma of the lung. Lung Cancer 1988 ; 4 (suppl.) : A54 (abstract 4.2.08).
92. Sorensen JB, Badsberg JH, Olsen J. Prognostic factors in inoperable adenocarcinoma of the lung : a multivariate regression analysis of 259 patients. Cancer Res 1989 ; 49 : 5748-54.
93. Takigawa N, Segawa Y, Okahara M, et al. Prognostic factors for patients with advanced non-small cell lung cancer : univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer 1996 ; 15 : 67-77.
94. Thorogood J, Bulmans AS, Collins T, Ash D. The use of discriminant analysis to guide palliative treatment for lung cancer patients. Clin Oncol 1992 ; 4 : 22-6.
95. Van der Gaast A, Schoenmakers CHH, Kok TC, Blijenberg BG, Hop WCJ, Splinter TAW. Prognostic significance of tissue polypeptide-specific antigen (TPS) in patients with advanced non-small cell lung cancer. Eur J Cancer 1994 ; 30A : 1783-6.
96. Van Zandwijk N, Jassem E, Bonfrer JMG, Mooi WJ, Van Tinteren H. Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer. Semin Oncol 1992 ; 19 (suppl. 2) : 37-43.
97. Wieskopf B, Demangeat C, Purohit A, et al. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Chest 1995 ; 108 : 163-9.
98. Bianco A, Marcatili P, D'Auria D, Sorrentino P, Zofra S. Marcatori tumorali scierici in pazienti con cancro del polmone. Ann Ital Med Int 1996 ; 11 : 114-8.
99. Buccheri G, Ferrigno D. Tissue polypeptide antigen (TPA) has a great prognostic capability in lung cancer (LC). Lung Cancer 1991 ; 7 (suppl.) : 47 (abstract 166).
100. Buccheri G, Ferrigno D. Prognostic value of tissue polypeptide antigen in lung cancer. Chest 1992 ; 101 : 1287-92.
101. Buccheri G, Ferrigno D, Ginardi C, Zuliani C. Haemostatic abnormalities in lung cancer : prognostic implications. Eur J Cancer 1997 ; 33 : 50-5.
102. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance static scoring in lung cancer : a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996 ; 32A: 1135-41.
103. Ferrigno D, Buccheri G. A comprehensive evaluation of serum ferritin levels in lung cancer patients. Lung Cancer 1992 ; 8 : 85-94.
104. Ferrigno D, Buccheri G, Camilla T. Prognosis and lung cancer : the contribution of plasma proteins. Oncology Reports 1995 ; 2 : 637-41.
105. Fournie GJ, Courtin JP, Laval F. et al. Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett 1995 ; 91 : 221-7.
106. Hamzaoui A, Thomas P, Castelnau O, Roux N, Roux F, Kleisbauer JP. Usefulness of longitudinal evaluation of Cyfra 21-1 variations in advanced lung cancer monitoring. Lung Cancer 1997 ; 16 : 191-202.
107. Katsumata N, Eguchi K, Fukuda M. et al. Serum levels of cytokines in patients with untreated primary lung cancer. Clin Cancer Res 1996 ; 2 : 553-9.
108. Muller T, Marshall RJ, Cooper EH, Watson DA, Walker DA, Mearns AJ. The role of serum tumour markers to aid the selection of lung cancer patients for surgery and the assessment of prognosis. Eur J Cancer Clin Oncol 1985 ; 21 : 1461-6.
109. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by Cyfra 21-1 Immunoradiometric assay as a marker of lung cancer. Cancer Res 1993 ; 53 : 61-6.
110. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980 ; 65 : 25-32.
111. Szturmowicz M, Sakowicz A, Rudzinski P, et al. The clinical value of Cyfra 21-1 estimation for lung cancer patients. Int J Biol Markers 1996 ; 11 : 172-7.
112. Takei Y, Minato K, Tsuchiya S, et al. Cyfra 21-1 : an indicator of survival and therapeutic effect in lung cancer. Oncology 1997 ; 54 : 43-7.
113. Charet JC, Watine J, Lepretre A, Raimbault C, Charet P. Orosomucoïd : Prealbumin Ratio in the monitoring of lung cancer. Clin Biochem 1996 ; 29 : 287-90.
114. Pujol JL, Grenier J, Michel FB. Neuron specific enolase (NSE) et cyfra 21-1 en cancérologie pulmonaire. Immunoanal Biol Spé 1993 ; 8 : 240-2.
115. Naruke T, Tsuchiya R, Kondo H, Asamura H, Nakayama H. Implications of staging in lung cancer. Chest 1997 ; 112 : 242S-8S.
116. Ward AM and the Committee on Plasma Protein. In : Proceedings of the XVI International Congress of Clinical Chemistry, London UK, 8th-12th July 1996 : 35-6.
117. Giraudet P, Coudon B, Postel P, Alexandre JA. Profils protéiques. Behring Diagnostic, Rueil-Malmaison. Editions Publigrafic, Poissy, 1992.
118. Ingelbleek Y, Carpentier Y. A pronostic inflammatory and nutritional index scoring critically ill patients. Internat J Vit Nutr Res 1985 ; 55 : 91-101.
119. Caldani C, Thyss A, Schneider M, Milano G, Buray L, Demard F. Orosomucoïd : prealbumin ratio - a marker of the host-tumor relationship in head and neck cancer. Eur J Cancer Clin Oncol 1988 ; 24 : 653-7.
120. Plaisier E, Mougenot B, Moulin B, Ronco P. Glomérulopathies paranéoplasiques. Médecine Thérapeutique 1997 ; 3 : 717-25.
121. Pedersen LM, Milman N. Microalbuminuria in patients with lung cancer. Eur J Cancer 1998 ; 34 : 76-80.
122. Moller Pedersen L, Milman N. Prevalence and prognostic significance of proteinuria in patients with lung cancer. Acta Oncologica 1996 ; 6 : 691-5.
123. Durand-Zalesky I, Rymer JC, Roudot-Thoraval F, Revuz J, Rosa J. Reducing unnecessary laboratory use with new test request form : example of tumour markers. Lancet 1993 ; 342 : 150-3.